<p><strong><strong>Adults with Rheumatoid Arthritis (RA)</strong>: Etanercept indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Etanercept can be initiated in combination with methotrexate (MTX) or used alone for the treatment of active rheumatoid arthritis (RA) in adults when one or more disease modifying antirheumatic drugs (DMARDs), including methotrexate (unless contraindicated), has proved inadequate.<br />
<br />
<strong>Pediatric patients with Juvenile Idiopathic Arthritis(JIA)</strong>: Etanercept indicated for the treatment of polyarticular-course juvenile idiopathic arthritis (JIA) in children and adolescents from the age of 2 years when the response to one or more DMARDs has proven inadequate.<br />
<br />
<strong>Adults with Psoriatic Arthritis (PsA)</strong>: Etanercept is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Etanercept can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone.<br />
<br />
<strong>Adults with Ankylosing Spondylitis (AS)</strong>: Etanerceptis indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).<br />
<br />
<strong>Adults with Plaque Psoriasis (PsO)</strong>: Etanercept is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.<br />
<br />
<strong>Pediatric patients with Plaque Psoriasis (PsO)</strong>: Etanercept is indicated for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years, who are inadequately controlled by or are intolerant to systemic therapies or phototherapies.</strong></p>